King's Research Portal

DOI:

[10.1007/s00134-018-5480-6](https://doi.org/10.1007/s00134-018-5480-6)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Shankar-Hari, M., Fan, E., & Ferguson, N. (2018). Acute Respiratory Distress Syndrome (ARDS) Phenotyping. *Intensive Care Medicine*. <https://doi.org/10.1007/s00134-018-5480-6>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Acute Respiratory Distress Syndrome (ARDS) Phenotyping

Running title: ARDS sub-phenotypes

Shankar-Hari M MSc PhD^{1,2}, Fan E^{3,4}, Ferguson ND^{3,4}

¹School of Immunology & Microbial Science, Kings College London, SE1 9RT; ²Guy's and St Thomas' NHS Foundation Trust, ICU support Offices, 1st Floor, East Wing, St Thomas' Hospital, SE1 7EH, UK; ³Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada;

⁴University Health Network and Sinai Health System, 585 University Avenue, PMB 11, Toronto, Ontario, M5G 2N2, Canada

Corresponding author:

Dr Manu Shankar-Hari MSc PhD FRCA FFICM

¹School of Immunology & Microbial Science, Kings College London, SE1 9RT; ²Guy's and St Thomas' NHS Foundation Trust, ICU support Offices, 1st Floor, East Wing, St Thomas' Hospital, SE1 7EH, UK
email: manu.shankar-hari@kcl.ac.uk

Tel: +44 20 7188 8769; Fax: +44 20 7188 2284

Author contributions

Dr Shankar-Hari wrote the first draft of the manuscript. All authors contributed towards the critical revision of the manuscript for important intellectual content and confirm the integrity of the work.

Sources of support:

Dr Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). Dr Fan is supported by a New Investigator Award from the Canadian Institutes of Health Research.

Conflicts of interests:

All authors declare that they do not have any personal conflict of interest directly related to this manuscript.

Acknowledgements:

This independent research by Dr Manu Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (NIHR-CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Manuscript details: Word count: 955 References: 13 Figure: 1

Clinically, the Berlin ARDS definition describes acute respiratory distress syndrome (ARDS) as acute hypoxemic respiratory failure, that is not fully explained by cardiac failure or fluid overload, that develops within seven days of clinical recognition of a known risk factor, with bilateral radiographic opacities that are not fully explained by effusions, lobar/lung collapse, or nodules. Three risk strata were defined, based on the severity of hypoxemia represented by the ratio of partial pressure of oxygen in arterial blood to inspired oxygen concentration ($\text{PaO}_2/\text{FiO}_2$ ratio), assessed at a minimum positive end-expiratory pressure (PEEP) of 5 centimetres of water [1]. Hospital mortality worsens with severity of hypoxaemia and thus grade of ARDS (from 35% in mild ARDS to 46% in severe ARDS) [1, 2].

The ARDS consensus definitions to-date have mainly relied on feasible clinical criteria, which helps to group patients together for inclusion in clinical trials and for clinical management [1, 3]. This generates clinical and biological differences in observable patient characteristics. These differences are associated with inter-individual variation in the risk of illness, risk of outcomes from the illness, response to treatments administered for the illness and combinations thereof (referred to as heterogeneity)[4, 5]. For example, pneumonia is a common risk factor for ARDS [2, 3, 6]. However, not every patient admitted with pneumonia develops ARDS. One possible explanation is that there are differences in host responses between patients, as observed by variation in biomarker profiles for the same risk factor [7]. Amongst patients with pneumonia who develop ARDS, the severity and outcome vary between cohorts. This ARDS heterogeneity has contributed towards many statistically negative randomised controlled trials (RCT) [6].

Thus, identifying subgroups of ARDS patients (referred to as ARDS sub-phenotypes in the literature) who either have a higher risk of mortality (prognostic enrichment), or differences in treatment responses and/or similar biological mechanisms that are modifiable (predictive enrichment) could enable stratified and/or precision medicine [5]. To-date, two ARDS sub-phenotypes have been reported from reanalyses of five RCTs [8-12], and in one observational cohort study [13], where the sub-phenotype membership was determined by similarities in the observable clinical and biological features. Although, all six studies report two ARDS sub-phenotypes, they differ in the biomarkers, clinical characteristics, and analytic approaches used. All RCT reanalyses used biomarker and clinical

characteristics with latent class analyses to determine ARDS sub-phenotypes [8-12]. All RCTs report a *hyperinflammatory* sub-phenotype characterised by higher plasma concentrations of inflammatory biomarkers, greater vasopressor use, lower serum bicarbonate concentrations, and a higher prevalence of sepsis, when compared to the more common hypoinflammatory (Phenotype-1) sub-phenotype [8-12]. This *hyperinflammatory* sub-phenotype has higher mortality (prognostic enrichment) and different treatment responses to PEEP, simvastatin, and fluid management (predictive enrichment) [8-11], which may reflect true biological effect modification. Importantly, these two phenotypes could be distinguished with a three-variable model of serum interleukin-8 (IL-8) or IL-6, bicarbonate, and soluble tumor necrosis factor receptor-1 (sTNFR-1), in patients enrolled within the ARDS Network RCTs of lower versus higher tidal volume ventilation (ARMA), higher versus lower positive end-expiratory pressure (ALVEOLI), and the Fluid and Catheter Treatment Trial (FACTT) [8, 9]. In contrast, the observational cohort study used only biomarker data with clustering analysis to determine ARDS sub-phenotypes [13]. The *reactive* sub-phenotype reported in the observational study had higher mortality when compared to the *uninflamed* sub-phenotype [13] and could be distinguished with a four-variable biomarker panel consisting of IL-6, interferon gamma, angiopoietin 1, angiopoietin 2, and plasminogen activator inhibitor-1 [Figure-1]. While up to a third of patients with ARDS progressed to more severe risk strata over the first 7 days [1, 2], these ARDS sub-phenotypes remained stable over first three days of enrolment into ARMA and ALVEOLI trials [11].

Prior to any attempts at incorporating management directed to ARDS sub-phenotypes into routine clinical practice, a number of important questions need to be answered. The prevalence of reactive sub-phenotypes was twice as common in the observational cohort study compared to the *hyperinflammatory* sub-phenotypes in RCTs. It is not clear if this is due to selection bias inherent to randomized trials or to differences in biology. We need to ascertain whether the *reactive and hyperinflammatory* sub-phenotypes are phenotypically and/or biologically similar. As infection is the most common risk factor for ARDS, similarities of ARDS sub-phenotypes to sepsis sub-phenotypes should be explored. Prospective validation studies with a standardised approach to ARDS sub-phenotyping are needed and could be an international inception cohort study similar to the LUNG-SAFE study [2]. As radiology and need for minimum PEEP are challenging elements of the Berlin Definition, acute hypoxemic respiratory failure (i.e., $\text{PaO}_2/\text{FiO}_2 \leq 300$ regardless of PEEP level) could

be the inception cohort, which then could be used to identify ARDS patients within the AHRF cohort. The study aims are then to determine similarities and differences between acute hypoxemic respiratory failure and ARDS, alongside validating ARDS sub-phenotypes. Studying biological signals in this context requires a comprehensive set of data of different biological dimensions (e.g., gene expression on leukocytes [leukocyte transcriptome], and altered patterns of protein components in blood [proteome], in addition to detailed clinical phenotyping). This research should resemble a system biology research cycle and could begin with the hypothesis that there are at least two biologically distinct ARDS sub-phenotypes and that these ARDS sub-phenotypes have differences in risk of death and treatment response. There is a clinical need to identify biomarkers that are associated with treatment response, independent of group membership. Therefore, consensus on biological sampling time-points, biological dimension measured, and a standard minimum set of consensus biomarkers is required. The biological sampling should aim to reflect the insults to the alveolar capillary membrane (ACM) (exudative phase), deposition of provisional matrix with proliferation of airway progenitor cells (proliferative phase), or interstitial and intra alveolar fibrosis (fibrotic phase) of ARDS. This minimum set of markers could then be used to delineate discriminant markers of ARDS sub-phenotypes that provide prognostic enrichment with either a greater probability of therapeutically valid similarities or a greater likelihood of treatment response.

Legend

Figure-1: ARDS Phenotyping

Broadly, the term phenotype refers to observable characteristics of an organism. The observable differences in clinical and biological characteristics could be used to group ARDS patients, referred to as ARDS sub-phenotypes. ARDS sub-phenotypes have been reported from five randomised controlled trials and one observational cohort study. There are differences in the variables and the method used to define ARDS sub-phenotypes, which are summarised in the figure.

¹The Respiratory system variables included minute ventilation, mean airway pressure, plateau pressure, respiratory rate, tidal volume, positive end-expiratory pressure; partial pressure PaO₂ of carbon dioxide (PaCO₂) and ratio of partial pressure of oxygen in arterial blood to inspired oxygen concentration (PaO₂/FiO₂ ratio). The Cardiovascular system variables include highest heart rate, lowest systolic blood pressure and vasopressor use. The renal variables included creatinine, urea and urine output. ANG1/2, angiotensin 1 and 2; BMI, body mass index; CRP – C reactive protein; GM-CSF, granulocyte-monocyte colony stimulating factor; HCO₃, bicarbonate; ICAM-1, intracellular adhesion molecule-1; IFN-γ, interferon gamma; IL, interleukins 6, 8, 10, 13; IL-1β, interleukin-1 beta; LDH – lactate dehydrogenase; MMP-8, matrix metalloproteinase-8; P/F, PaO₂/FiO₂ ratio; PAI-1, plasminogen activator inhibitor-1; PCT – procalcitonin; sRAGE, soluble receptor for advanced glycation end products; RCT, randomised controlled trial; SP-D, surfactant protein-D; sTNFR-1, soluble tumour necrosis factor receptor-1; TIMP-1, tissue inhibitor of metalloproteinase-1; TNF-α, tumor necrosis factor-alpha; TNFR – tumor necrosis factor receptor; tPA, tissue plasminogen activator; vWF, von-Willebrand's factor; VeGF – vascular endothelial growth factor; WBC, white blood cell count.

References

1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526-2533
2. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, Investigators LS, Group ET, (2016) Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA 315: 788-800
3. Thompson BT, Chambers RC, Liu KD, (2017) Acute Respiratory Distress Syndrome. N Engl J Med 377: 562-572
4. Shankar-Hari M, Rubenfeld GD, (2017) The use of enrichment to reduce statistically indeterminate or negative trials in critical care. Anaesthesia 72: 560-565
5. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX, (2016) Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. Am J Respir Crit Care Med 194: 147-155
6. Fan E, Brodie D, Slutsky AS, (2018) Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA 319: 698-710
7. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB, (2014) Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med 42: 691-700
8. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Network NA, (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. The Lancet Respiratory medicine 2: 611-620
9. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS, Network A, (2017) Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med 195: 331-338
10. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials G, (2018) Acute respiratory

distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *The Lancet Respiratory medicine* 6: 691-698

11. Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, Network A, (2018) Stability of ARDS subphenotypes over time in two randomised controlled trials. *Thorax* 73: 439-445
12. Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS, Network NA, (2018) Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Med* 44: 1859-1869
13. Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, Artigas A, Martin-Loeches I, Hoogendijk AJ, van der Poll T, Horn J, Juffermans N, Calfee CS, Schultz MJ, consortium M, (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax* 72: 876-883